Latest Development Pipeline News

Mesoblast Limited is set to release its half-year financial results and operational update, spotlighting its FDA-approved cell therapy and expanding international partnerships.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing for its lead ophthalmology product, Elate Ocular®, alongside key global partnerships and a $2.4 million capital injection from a major shareholder.

Newmont Corporation’s 2025 Annual Report reveals a robust financial performance driven by higher gold prices and portfolio optimisation, alongside significant progress in key development projects and sustainability initiatives.

Peet Limited has reported a robust half-year performance with statutory profit doubling and a significant dividend increase, underpinned by strong sales and settlements across key Australian markets.

Aspen Group Limited reported a robust half-year result for December 2025, with statutory profit up 15% and a 51% surge in underlying earnings, driven by rental portfolio expansion and accelerated development settlements.

Charter Hall Group has reported a strong first half for FY26, with operating earnings surging 21.6% and record equity inflows driving funds under management to $92.2 billion. The group has upgraded its full-year earnings guidance, signalling confidence amid ongoing market volatility.

Goodman Group reported a slight dip in operating profit for the half year ended 31 December 2025, while statutory profit rose and the total portfolio value expanded to $87.4 billion. The group maintained its interim distribution at 15 cents per security amid ongoing investment in logistics and digital infrastructure.

Vicinity Centres reports a robust FY26 interim profit of $805.6 million, driven by strong leasing and portfolio premiumisation, including the strategic acquisition of Uptown in Brisbane.

Vicinity Centres reported a strong first half of FY26 with a statutory net profit of $805.6 million, strategic acquisitions including full ownership of Uptown Brisbane, and reaffirmed guidance for the full year.

Dexus has announced a new on-market buyback of up to 10% of its securities, aiming to address the disconnect between its market valuation and underlying asset values while maintaining capital discipline.

Dexus has reported a strong half-year result with a $348.5 million profit turnaround, robust leasing growth, and strategic capital moves including a $950 million equity raise and a 10% on-market buyback.

Vicinity Centres reported a strong first half of FY26, boosting profits and advancing key retail and mixed-use developments, while maintaining a conservative balance sheet.